Outlook Therapeutics
OTLK
53 hedge funds and large institutions have $10.8M invested in Outlook Therapeutics in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 19 increasing their positions, 7 reducing their positions, and 8 closing their positions.
171% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 7
149% more capital invested
Capital invested by funds: $4.32M → $10.8M (+$6.46M)
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
1.46% more ownership
Funds ownership: 9.18% → 10.64% (+1.5%)
2% less funds holding
Funds holding: 54 → 53 (-1)
67% less call options, than puts
Call options by funds: $1.26M | Put options by funds: $3.89M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$2.76M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$477K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$258K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$196K |
| 5 |
State Street
Boston,
Massachusetts
|
+$140K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$144K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$63K |
| 3 |
Millennium Management
New York
|
-$48.1K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$37.8K |
| 5 |
SA
Sanctuary Advisors
Indianapolis,
Indiana
|
-$35.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SPIA
51
Steward Partners Investment Advisory
New York
| $22 | – | – | – |
|
52
Barclays
London,
United Kingdom
| $2 | – | – | – |
|
|
TSS
53
Two Sigma Securities
New York
| – | -$37.8K | -35,664 | Closed |
|
|
SA
54
Sanctuary Advisors
Indianapolis,
Indiana
| – | -$35.5K | -33,495 | Closed |
|
55
Russell Investments Group
London,
United Kingdom
| – | -$16.4K | -15,498 | Closed |
|
56
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$14.1K | -13,347 | Closed |
|
|
OC
57
Oppenheimer & Co
New York
| – | -$13.8K | -13,000 | Closed |
|
58
Two Sigma Investments
New York
| – | -$12K | -11,356 | Closed |
|
|
WANY
59
Wealthspire Advisors (New York)
New York
| – | -$318 | -300 | Closed |
|
|
TCM
60
Tradewinds Capital Management
Bellingham,
Washington
| – | -$106 | -100 | Closed |
|
OTLK Hedge Fund Activity: Q4 2025 in Review
53 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q4 2025, worth a combined $10.8M — up 149% from $4.32M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new OTLK positions and 8 closed out — a net gain of 1 holder — while 19 added to existing stakes and 7 trimmed.
The largest buyer was Schonfeld Strategic Advisors, adding an estimated $2.76M. The largest seller was Bank of America, cutting an estimated $144K.
- 53 institutional investors held Outlook Therapeutics (OTLK) as of Q4 2025, down from 54 in Q3 2025.
- Funds reported $10.8M of Outlook Therapeutics stock for Q4 2025, up 149% quarter-over-quarter.
- 9 funds opened new Outlook Therapeutics positions in Q4 2025 and 8 closed out, a net change of +1 holder.
- The largest Outlook Therapeutics buyer in Q4 2025 was Schonfeld Strategic Advisors, an estimated $2.76M added.
- The largest Outlook Therapeutics seller in Q4 2025 was Bank of America, an estimated $144K sold.
Based on aggregated 13F filings for Q4 2025.